Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Maravai Lifesciences Holdings (MRVI) EPS (Weighted Average and Diluted) (2020 - 2025)

Maravai Lifesciences Holdings (MRVI) has 6 years of EPS (Weighted Average and Diluted) data on record, last reported at -$0.24 in Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 33.33% year-over-year to -$0.24; the TTM value through Dec 2025 reached -$0.9, up 11.76%, while the annual FY2025 figure was -$0.9, 14.29% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.24 in Q4 2025 per MRVI's latest filing, down from -$0.18 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.53 in Q2 2022 and bottomed at -$0.8 in Q4 2023.
  • Average EPS (Weighted Average and Diluted) over 5 years is $0.02, with a median of -$0.05 recorded in 2023.
  • Peak YoY movement for EPS (Weighted Average and Diluted): skyrocketed 7647.81% in 2021, then crashed 1260.0% in 2024.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $0.43 in 2021, then plummeted by 30.23% to $0.3 in 2022, then plummeted by 366.67% to -$0.8 in 2023, then surged by 77.5% to -$0.18 in 2024, then crashed by 33.33% to -$0.24 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were -$0.24 in Q4 2025, -$0.18 in Q3 2025, and -$0.27 in Q2 2025.